The estimated Net Worth of Yu Waye Chu is at least 1.21 百万$ dollars as of 18 April 2023. Yu Chu owns over 2,532 units of Fate Therapeutics Inc stock worth over 545,823$ and over the last 4 years he sold FATE stock worth over 666,461$. In addition, he makes 0$ as Vice President - Clinical Development at Fate Therapeutics Inc.
Yu has made over 6 trades of the Fate Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,532 units of FATE stock worth 16,635$ on 18 April 2023.
The largest trade he's ever made was selling 7,825 units of Fate Therapeutics Inc stock on 10 January 2023 worth over 41,003$. On average, Yu trades about 2,651 units every 67 days since 2021. As of 18 April 2023 he still owns at least 140,676 units of Fate Therapeutics Inc stock.
You can see the complete history of Yu Chu stock trades at the bottom of the page.
Yu-Waye Chu is the Vice President - Clinical Development at Fate Therapeutics Inc.
Yu's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over 48,476,146$ worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth 162,421,037$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Associates V Lpvenrock Part...、Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of 384,496$. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth 2,678$.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: